Skip to main content

Table 12 Plasma miRNA results in MD patients with vs. without presence of LGE

From: Identification of cardiomyopathy associated circulating miRNA biomarkers in patients with muscular dystrophy using a complementary cardiovascular magnetic resonance and plasma profiling approach

miRNA plasma levelsa (/103)

LGE-negative

LGE-positive

p value

N = 15

N = 48

-206

13.18 (3.69–43.72)

22.85 (4.56–74.83)

0.54

-144-5p

15.70 (0.00–159.39)

4.93 (0.00–191.57)

0.95

-146b

81.86 (32.74–162.66)

44.23 (0.00–177.79)

0.32

-15b

7.42 (0.00–21.10)

0.00 (0.00–19.01)

0.41

-195

10.50 (2.70–17.48)

8.19 (0.54–21.93)

0.75

-20b

46.56 (31.69–74.64)

65.45 (19.35–86.58)

0.58

-21

67.48 (5.74–106.23)

11.82 (0.00–115.78)

0.65

-221

0.00 (0.00–32.92)

0.00 (0.00–10.03)

0.66

-222

1288.92 (355.69–1728.72)

2303.59 (1102.54–6059.36)

0.035

-26a

165.39 (36.75–291.31)

345.01 (139.78–616.20)

0.030

-29a

0.00 (0.00–.09)

0.00 (0.00–0.00)

0.61

-29c

0.00 (0.00–2.14)

0.00 (0.00–.65)

0.89

-342

1906.24 (491.08–2603.63)

2668.49 (1512.77–5205.06)

0.07

-378a-3p

13.18 (0.00–155.98)

40.31 (8.05–301.61)

0.26

-378a-5p

16.99 (1.04–36.13)

41.23 (14.62–102.03)

0.026

-451

106.88 (64.56–273.40)

207.05 (100.16–340.80)

0.29

-93

23.85 (0.77–52.24)

27.17 (0.00–70.37)

0.89

  1. (a) – Each miRNA plasma level was normalized to miR-16 plasma levels and thereafter multiplied by 103 in order to increase readability
  2. Bold text indicates a significant p-value of <0.05